Per analysts, RXRX stock represents a moderate buy . Further, the average price target lands at $17, implying over 102% upside potential. For the current fiscal year, experts anticipate Recursion to post a loss per share of $1.72. Admittedly, that’s worse than last year’s red ink of $1.58. That said, the most optimistic assessment calls for a loss of $1.49. To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. Portfolio strategists recommend watching for January effect inflows that may push OTLK higher.
